nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—ABCB1—Topotecan—cervical cancer	0.333	0.625	CbGbCtD
Clomipramine—CYP3A4—Topotecan—cervical cancer	0.199	0.375	CbGbCtD
Clomipramine—GSTP1—exocrine gland—cervical cancer	0.018	0.0768	CbGeAlD
Clomipramine—Paresis—Topotecan—cervical cancer	0.0163	0.077	CcSEcCtD
Clomipramine—Intestinal obstruction—Topotecan—cervical cancer	0.00871	0.0412	CcSEcCtD
Clomipramine—Neuralgia—Topotecan—cervical cancer	0.00854	0.0404	CcSEcCtD
Clomipramine—GSTP1—epithelium—cervical cancer	0.00781	0.0334	CbGeAlD
Clomipramine—Rash erythematous—Topotecan—cervical cancer	0.00775	0.0367	CcSEcCtD
Clomipramine—GSTP1—uterine cervix—cervical cancer	0.00775	0.0331	CbGeAlD
Clomipramine—GSTP1—decidua—cervical cancer	0.00738	0.0316	CbGeAlD
Clomipramine—GSTP1—renal system—cervical cancer	0.00725	0.031	CbGeAlD
Clomipramine—GSTP1—endometrium—cervical cancer	0.00701	0.03	CbGeAlD
Clomipramine—GSTP1—mammalian vulva—cervical cancer	0.00678	0.029	CbGeAlD
Clomipramine—Dysmenorrhoea—Topotecan—cervical cancer	0.00653	0.0309	CcSEcCtD
Clomipramine—GSTP1—uterus—cervical cancer	0.00646	0.0276	CbGeAlD
Clomipramine—HTR2B—uterine cervix—cervical cancer	0.00639	0.0273	CbGeAlD
Clomipramine—HTR2B—decidua—cervical cancer	0.00609	0.026	CbGeAlD
Clomipramine—Respiratory failure—Topotecan—cervical cancer	0.00604	0.0286	CcSEcCtD
Clomipramine—GSTP1—female reproductive system—cervical cancer	0.00581	0.0248	CbGeAlD
Clomipramine—HTR2B—endometrium—cervical cancer	0.00578	0.0247	CbGeAlD
Clomipramine—Colitis—Topotecan—cervical cancer	0.0057	0.027	CcSEcCtD
Clomipramine—Neuropathy—Topotecan—cervical cancer	0.00557	0.0264	CcSEcCtD
Clomipramine—SLC6A2—decidua—cervical cancer	0.00541	0.0231	CbGeAlD
Clomipramine—Rash maculo-papular—Topotecan—cervical cancer	0.00539	0.0255	CcSEcCtD
Clomipramine—HTR2B—uterus—cervical cancer	0.00533	0.0228	CbGeAlD
Clomipramine—GSTP1—female gonad—cervical cancer	0.00528	0.0226	CbGeAlD
Clomipramine—GSTP1—vagina—cervical cancer	0.00525	0.0224	CbGeAlD
Clomipramine—HTR2C—female reproductive system—cervical cancer	0.0051	0.0218	CbGeAlD
Clomipramine—Ear pain—Topotecan—cervical cancer	0.00505	0.0239	CcSEcCtD
Clomipramine—SLC6A4—female reproductive system—cervical cancer	0.00483	0.0206	CbGeAlD
Clomipramine—HTR2B—female reproductive system—cervical cancer	0.00479	0.0205	CbGeAlD
Clomipramine—HRH2—lymph node—cervical cancer	0.00472	0.0202	CbGeAlD
Clomipramine—Anaphylactoid reaction—Topotecan—cervical cancer	0.00445	0.0211	CcSEcCtD
Clomipramine—HTR2B—vagina—cervical cancer	0.00433	0.0185	CbGeAlD
Clomipramine—SLC6A2—female reproductive system—cervical cancer	0.00425	0.0182	CbGeAlD
Clomipramine—Cardiac arrest—Topotecan—cervical cancer	0.0041	0.0194	CcSEcCtD
Clomipramine—CYP1A2—renal system—cervical cancer	0.00408	0.0174	CbGeAlD
Clomipramine—ADRA2A—uterine cervix—cervical cancer	0.00401	0.0172	CbGeAlD
Clomipramine—ADRA2A—decidua—cervical cancer	0.00382	0.0163	CbGeAlD
Clomipramine—ADRA2A—endometrium—cervical cancer	0.00363	0.0155	CbGeAlD
Clomipramine—CYP2C19—vagina—cervical cancer	0.00362	0.0155	CbGeAlD
Clomipramine—Pancytopenia—Topotecan—cervical cancer	0.00354	0.0167	CcSEcCtD
Clomipramine—ADRA2A—mammalian vulva—cervical cancer	0.00351	0.015	CbGeAlD
Clomipramine—HTR2A—epithelium—cervical cancer	0.00344	0.0147	CbGeAlD
Clomipramine—GSTP1—lymph node—cervical cancer	0.0034	0.0145	CbGeAlD
Clomipramine—Weight increased—Topotecan—cervical cancer	0.00339	0.016	CcSEcCtD
Clomipramine—ADRA2A—uterus—cervical cancer	0.00334	0.0143	CbGeAlD
Clomipramine—Pneumonia—Topotecan—cervical cancer	0.00334	0.0158	CcSEcCtD
Clomipramine—Neuropathy peripheral—Topotecan—cervical cancer	0.00325	0.0154	CcSEcCtD
Clomipramine—HTR2A—renal system—cervical cancer	0.00319	0.0136	CbGeAlD
Clomipramine—Sweating—Topotecan—cervical cancer	0.00318	0.0151	CcSEcCtD
Clomipramine—Hepatobiliary disease—Topotecan—cervical cancer	0.00314	0.0149	CcSEcCtD
Clomipramine—Epistaxis—Topotecan—cervical cancer	0.00313	0.0148	CcSEcCtD
Clomipramine—ADRA2A—female reproductive system—cervical cancer	0.00301	0.0128	CbGeAlD
Clomipramine—Rhinitis—Topotecan—cervical cancer	0.00299	0.0141	CcSEcCtD
Clomipramine—Hypoaesthesia—Topotecan—cervical cancer	0.00297	0.014	CcSEcCtD
Clomipramine—Pharyngitis—Topotecan—cervical cancer	0.00296	0.014	CcSEcCtD
Clomipramine—CYP3A4—renal system—cervical cancer	0.00295	0.0126	CbGeAlD
Clomipramine—ALB—lymph node—cervical cancer	0.00291	0.0124	CbGeAlD
Clomipramine—CYP2D6—renal system—cervical cancer	0.00291	0.0124	CbGeAlD
Clomipramine—HTR2B—lymph node—cervical cancer	0.0028	0.012	CbGeAlD
Clomipramine—ADRA2A—female gonad—cervical cancer	0.00274	0.0117	CbGeAlD
Clomipramine—ADRA2A—vagina—cervical cancer	0.00272	0.0116	CbGeAlD
Clomipramine—Angiopathy—Topotecan—cervical cancer	0.0027	0.0128	CcSEcCtD
Clomipramine—Immune system disorder—Topotecan—cervical cancer	0.00269	0.0127	CcSEcCtD
Clomipramine—Mediastinal disorder—Topotecan—cervical cancer	0.00269	0.0127	CcSEcCtD
Clomipramine—Chills—Topotecan—cervical cancer	0.00267	0.0127	CcSEcCtD
Clomipramine—Alopecia—Topotecan—cervical cancer	0.00263	0.0125	CcSEcCtD
Clomipramine—Malnutrition—Topotecan—cervical cancer	0.00259	0.0123	CcSEcCtD
Clomipramine—HTR2A—female reproductive system—cervical cancer	0.00256	0.0109	CbGeAlD
Clomipramine—Back pain—Topotecan—cervical cancer	0.00251	0.0119	CcSEcCtD
Clomipramine—Muscle spasms—Topotecan—cervical cancer	0.00249	0.0118	CcSEcCtD
Clomipramine—SLC6A2—lymph node—cervical cancer	0.00249	0.0106	CbGeAlD
Clomipramine—Ill-defined disorder—Topotecan—cervical cancer	0.00241	0.0114	CcSEcCtD
Clomipramine—Anaemia—Topotecan—cervical cancer	0.0024	0.0113	CcSEcCtD
Clomipramine—CYP3A4—female reproductive system—cervical cancer	0.00237	0.0101	CbGeAlD
Clomipramine—Malaise—Topotecan—cervical cancer	0.00234	0.0111	CcSEcCtD
Clomipramine—CYP2D6—female reproductive system—cervical cancer	0.00233	0.00995	CbGeAlD
Clomipramine—Leukopenia—Topotecan—cervical cancer	0.00232	0.011	CcSEcCtD
Clomipramine—HTR2A—vagina—cervical cancer	0.00231	0.00988	CbGeAlD
Clomipramine—Cough—Topotecan—cervical cancer	0.00226	0.0107	CcSEcCtD
Clomipramine—ABCB1—epithelium—cervical cancer	0.00226	0.00964	CbGeAlD
Clomipramine—ABCB1—uterine cervix—cervical cancer	0.00224	0.00956	CbGeAlD
Clomipramine—Arthralgia—Topotecan—cervical cancer	0.00221	0.0105	CcSEcCtD
Clomipramine—Myalgia—Topotecan—cervical cancer	0.00221	0.0105	CcSEcCtD
Clomipramine—Chest pain—Topotecan—cervical cancer	0.00221	0.0105	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00219	0.0104	CcSEcCtD
Clomipramine—Discomfort—Topotecan—cervical cancer	0.00218	0.0103	CcSEcCtD
Clomipramine—ABCB1—decidua—cervical cancer	0.00213	0.0091	CbGeAlD
Clomipramine—CYP2D6—female gonad—cervical cancer	0.00212	0.00906	CbGeAlD
Clomipramine—Anaphylactic shock—Topotecan—cervical cancer	0.00212	0.01	CcSEcCtD
Clomipramine—ABCB1—renal system—cervical cancer	0.00209	0.00894	CbGeAlD
Clomipramine—Nervous system disorder—Topotecan—cervical cancer	0.00208	0.00983	CcSEcCtD
Clomipramine—Thrombocytopenia—Topotecan—cervical cancer	0.00207	0.00981	CcSEcCtD
Clomipramine—Skin disorder—Topotecan—cervical cancer	0.00206	0.00973	CcSEcCtD
Clomipramine—Hyperhidrosis—Topotecan—cervical cancer	0.00205	0.00969	CcSEcCtD
Clomipramine—ABCB1—endometrium—cervical cancer	0.00202	0.00864	CbGeAlD
Clomipramine—Anorexia—Topotecan—cervical cancer	0.00202	0.00955	CcSEcCtD
Clomipramine—ABCB1—mammalian vulva—cervical cancer	0.00196	0.00836	CbGeAlD
Clomipramine—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00193	0.00913	CcSEcCtD
Clomipramine—Paraesthesia—Topotecan—cervical cancer	0.0019	0.009	CcSEcCtD
Clomipramine—Dyspnoea—Topotecan—cervical cancer	0.00189	0.00893	CcSEcCtD
Clomipramine—Dyspepsia—Topotecan—cervical cancer	0.00186	0.00882	CcSEcCtD
Clomipramine—ABCB1—uterus—cervical cancer	0.00186	0.00796	CbGeAlD
Clomipramine—Decreased appetite—Topotecan—cervical cancer	0.00184	0.00871	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Topotecan—cervical cancer	0.00183	0.00865	CcSEcCtD
Clomipramine—Fatigue—Topotecan—cervical cancer	0.00183	0.00864	CcSEcCtD
Clomipramine—Constipation—Topotecan—cervical cancer	0.00181	0.00857	CcSEcCtD
Clomipramine—Pain—Topotecan—cervical cancer	0.00181	0.00857	CcSEcCtD
Clomipramine—ADRA2A—lymph node—cervical cancer	0.00176	0.00752	CbGeAlD
Clomipramine—Feeling abnormal—Topotecan—cervical cancer	0.00174	0.00826	CcSEcCtD
Clomipramine—Gastrointestinal pain—Topotecan—cervical cancer	0.00173	0.00819	CcSEcCtD
Clomipramine—Urticaria—Topotecan—cervical cancer	0.00168	0.00796	CcSEcCtD
Clomipramine—ABCB1—female reproductive system—cervical cancer	0.00168	0.00716	CbGeAlD
Clomipramine—Abdominal pain—Topotecan—cervical cancer	0.00167	0.00792	CcSEcCtD
Clomipramine—Body temperature increased—Topotecan—cervical cancer	0.00167	0.00792	CcSEcCtD
Clomipramine—HRH2—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00156	0.0684	CbGpPWpGaD
Clomipramine—Hypersensitivity—Topotecan—cervical cancer	0.00156	0.00738	CcSEcCtD
Clomipramine—ABCB1—female gonad—cervical cancer	0.00152	0.00651	CbGeAlD
Clomipramine—Asthenia—Topotecan—cervical cancer	0.00152	0.00719	CcSEcCtD
Clomipramine—ABCB1—vagina—cervical cancer	0.00152	0.00648	CbGeAlD
Clomipramine—Pruritus—Topotecan—cervical cancer	0.0015	0.00709	CcSEcCtD
Clomipramine—Diarrhoea—Topotecan—cervical cancer	0.00145	0.00686	CcSEcCtD
Clomipramine—Dizziness—Topotecan—cervical cancer	0.0014	0.00663	CcSEcCtD
Clomipramine—Vomiting—Topotecan—cervical cancer	0.00135	0.00637	CcSEcCtD
Clomipramine—Rash—Topotecan—cervical cancer	0.00133	0.00632	CcSEcCtD
Clomipramine—Dermatitis—Topotecan—cervical cancer	0.00133	0.00631	CcSEcCtD
Clomipramine—Headache—Topotecan—cervical cancer	0.00133	0.00628	CcSEcCtD
Clomipramine—Nausea—Topotecan—cervical cancer	0.00126	0.00595	CcSEcCtD
Clomipramine—HTR6—Amine ligand-binding receptors—TAAR6—cervical cancer	0.0012	0.0524	CbGpPWpGaD
Clomipramine—HTR2B—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00109	0.0479	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.000997	0.0437	CbGpPWpGaD
Clomipramine—ABCB1—lymph node—cervical cancer	0.00098	0.00419	CbGeAlD
Clomipramine—HTR2C—Amine ligand-binding receptors—TAAR6—cervical cancer	0.000881	0.0386	CbGpPWpGaD
Clomipramine—HTR2A—Amine ligand-binding receptors—TAAR6—cervical cancer	0.000765	0.0335	CbGpPWpGaD
Clomipramine—HTR2A—Serotonin Receptor 2 and STAT3 Signaling—STAT3—cervical cancer	0.000733	0.0321	CbGpPWpGaD
Clomipramine—ADRA2A—Amine ligand-binding receptors—TAAR6—cervical cancer	0.000696	0.0305	CbGpPWpGaD
Clomipramine—HRH2—G alpha (s) signalling events—TAAR6—cervical cancer	0.000644	0.0282	CbGpPWpGaD
Clomipramine—HTR6—G alpha (s) signalling events—TAAR6—cervical cancer	0.000494	0.0216	CbGpPWpGaD
Clomipramine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000351	0.0154	CbGpPWpGaD
Clomipramine—GSTP1—Cellular responses to stress—CA9—cervical cancer	0.000347	0.0152	CbGpPWpGaD
Clomipramine—HRH2—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000307	0.0134	CbGpPWpGaD
Clomipramine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.00028	0.0123	CbGpPWpGaD
Clomipramine—SLC6A4—Circadian rythm related genes—UBE3A—cervical cancer	0.000274	0.012	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.000273	0.012	CbGpPWpGaD
Clomipramine—CYP1A2—Tryptophan metabolism—UBE3A—cervical cancer	0.00027	0.0118	CbGpPWpGaD
Clomipramine—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.000243	0.0106	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.000239	0.0105	CbGpPWpGaD
Clomipramine—HTR6—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000235	0.0103	CbGpPWpGaD
Clomipramine—HRH2—GPCR ligand binding—TAAR6—cervical cancer	0.000234	0.0102	CbGpPWpGaD
Clomipramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000216	0.00946	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.000216	0.00944	CbGpPWpGaD
Clomipramine—HTR2B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000215	0.00941	CbGpPWpGaD
Clomipramine—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000208	0.00911	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.000188	0.00825	CbGpPWpGaD
Clomipramine—HRH2—GPCR ligand binding—WNT2—cervical cancer	0.000182	0.00799	CbGpPWpGaD
Clomipramine—HTR6—GPCR ligand binding—TAAR6—cervical cancer	0.000179	0.00785	CbGpPWpGaD
Clomipramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000173	0.00759	CbGpPWpGaD
Clomipramine—HTR2B—GPCR ligand binding—TAAR6—cervical cancer	0.000164	0.00717	CbGpPWpGaD
Clomipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000151	0.00659	CbGpPWpGaD
Clomipramine—SLC6A4—SIDS Susceptibility Pathways—HES1—cervical cancer	0.000149	0.00651	CbGpPWpGaD
Clomipramine—CYP1A2—Estrogen Receptor Pathway—STAT3—cervical cancer	0.000143	0.00628	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—SERPIND1—cervical cancer	0.000141	0.00617	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—GP6—cervical cancer	0.000141	0.00617	CbGpPWpGaD
Clomipramine—HTR6—GPCR ligand binding—WNT2—cervical cancer	0.00014	0.00613	CbGpPWpGaD
Clomipramine—HRH2—GPCR ligand binding—WNT5A—cervical cancer	0.000138	0.00606	CbGpPWpGaD
Clomipramine—ALB—Vitamin B12 Metabolism—MTHFR—cervical cancer	0.000138	0.00605	CbGpPWpGaD
Clomipramine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000137	0.006	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—TAAR6—cervical cancer	0.000132	0.00579	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—TAAR6—cervical cancer	0.000132	0.00578	CbGpPWpGaD
Clomipramine—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.000131	0.00573	CbGpPWpGaD
Clomipramine—HTR2B—GPCR ligand binding—WNT2—cervical cancer	0.000128	0.0056	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—GP5—cervical cancer	0.000123	0.00539	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—TAAR6—cervical cancer	0.00012	0.00525	CbGpPWpGaD
Clomipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.000119	0.00523	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—TAAR6—cervical cancer	0.000115	0.00502	CbGpPWpGaD
Clomipramine—ALB—Folate Metabolism—MTHFR—cervical cancer	0.000112	0.00492	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—SERPIND1—cervical cancer	0.000111	0.00487	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—GP6—cervical cancer	0.000111	0.00487	CbGpPWpGaD
Clomipramine—HTR6—GPCR ligand binding—WNT5A—cervical cancer	0.000106	0.00465	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—TAAR6—cervical cancer	0.000104	0.00457	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—WNT2—cervical cancer	0.000103	0.00451	CbGpPWpGaD
Clomipramine—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	0.000102	0.00447	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—TAAR6—cervical cancer	0.000101	0.00444	CbGpPWpGaD
Clomipramine—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	9.81e-05	0.0043	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—GP5—cervical cancer	9.71e-05	0.00425	CbGpPWpGaD
Clomipramine—HTR2B—GPCR ligand binding—WNT5A—cervical cancer	9.68e-05	0.00424	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—WNT2—cervical cancer	9.36e-05	0.0041	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—TAAR6—cervical cancer	9.25e-05	0.00405	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—TAAR6—cervical cancer	9.2e-05	0.00403	CbGpPWpGaD
Clomipramine—GSTP1—Cellular responses to stress—MTOR—cervical cancer	9.07e-05	0.00398	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—AKAP13—cervical cancer	9.05e-05	0.00397	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—WNT2—cervical cancer	8.95e-05	0.00392	CbGpPWpGaD
Clomipramine—HTR2A—SIDS Susceptibility Pathways—HES1—cervical cancer	8.95e-05	0.00392	CbGpPWpGaD
Clomipramine—ALB—Selenium Micronutrient Network—MTHFR—cervical cancer	8.92e-05	0.00391	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	8.81e-05	0.00386	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—TAAR6—cervical cancer	8.4e-05	0.00368	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—CA9—cervical cancer	8.37e-05	0.00367	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—AKAP13—cervical cancer	8.22e-05	0.0036	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—WNT2—cervical cancer	8.14e-05	0.00357	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—WNT5A—cervical cancer	7.81e-05	0.00342	CbGpPWpGaD
Clomipramine—SLC6A4—SIDS Susceptibility Pathways—CASP3—cervical cancer	7.73e-05	0.00339	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—TAAR6—cervical cancer	7.46e-05	0.00327	CbGpPWpGaD
Clomipramine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	7.45e-05	0.00327	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—WNT2—cervical cancer	7.18e-05	0.00315	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—WNT5A—cervical cancer	7.1e-05	0.00311	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TAAR6—cervical cancer	7.08e-05	0.0031	CbGpPWpGaD
Clomipramine—GSTP1—Cellular responses to stress—STAT3—cervical cancer	7.01e-05	0.00307	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—AKAP13—cervical cancer	6.94e-05	0.00304	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—WNT5A—cervical cancer	6.78e-05	0.00297	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—TAAR6—cervical cancer	6.77e-05	0.00297	CbGpPWpGaD
Clomipramine—ABCB1—Allograft Rejection—CASP8—cervical cancer	6.67e-05	0.00292	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—WNT2—cervical cancer	6.55e-05	0.00287	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—TAAR6—cervical cancer	6.48e-05	0.00284	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—AKAP13—cervical cancer	6.34e-05	0.00278	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—AKAP13—cervical cancer	6.3e-05	0.00276	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—WNT5A—cervical cancer	6.17e-05	0.0027	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—TAAR6—cervical cancer	5.89e-05	0.00258	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—TAAR6—cervical cancer	5.88e-05	0.00258	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—AKAP13—cervical cancer	5.75e-05	0.00252	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—WNT2—cervical cancer	5.53e-05	0.00242	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—WNT5A—cervical cancer	5.44e-05	0.00238	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TAAR6—cervical cancer	5.43e-05	0.00238	CbGpPWpGaD
Clomipramine—GSTP1—Cellular responses to stress—TP53—cervical cancer	5.35e-05	0.00234	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—TAAR6—cervical cancer	5.35e-05	0.00234	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—WNT2—cervical cancer	5.29e-05	0.00232	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—AKAP13—cervical cancer	5.11e-05	0.00224	CbGpPWpGaD
Clomipramine—ABCB1—Allograft Rejection—CASP3—cervical cancer	5.05e-05	0.00221	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—WNT5A—cervical cancer	4.97e-05	0.00218	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TAAR6—cervical cancer	4.96e-05	0.00217	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—AKAP13—cervical cancer	4.86e-05	0.00213	CbGpPWpGaD
Clomipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	4.74e-05	0.00208	CbGpPWpGaD
Clomipramine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	4.74e-05	0.00208	CbGpPWpGaD
Clomipramine—HTR2A—SIDS Susceptibility Pathways—CASP3—cervical cancer	4.65e-05	0.00204	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—AKAP13—cervical cancer	4.64e-05	0.00203	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—WNT2—cervical cancer	4.59e-05	0.00201	CbGpPWpGaD
Clomipramine—HTR2A—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	4.49e-05	0.00197	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—AKAP13—cervical cancer	4.44e-05	0.00194	CbGpPWpGaD
Clomipramine—ALB—Folate Metabolism—TP53—cervical cancer	4.26e-05	0.00187	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—WNT2—cervical cancer	4.24e-05	0.00186	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—WNT5A—cervical cancer	4.19e-05	0.00184	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—WNT2—cervical cancer	4.18e-05	0.00183	CbGpPWpGaD
Clomipramine—SLC6A4—Circadian rythm related genes—TP53—cervical cancer	4.05e-05	0.00177	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—AKAP13—cervical cancer	4.04e-05	0.00177	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—AKAP13—cervical cancer	4.03e-05	0.00177	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—WNT5A—cervical cancer	4.01e-05	0.00176	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TAAR6—cervical cancer	4e-05	0.00175	CbGpPWpGaD
Clomipramine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	3.93e-05	0.00172	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—WNT2—cervical cancer	3.87e-05	0.0017	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—AKAP13—cervical cancer	3.72e-05	0.00163	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—AKAP13—cervical cancer	3.67e-05	0.00161	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—WNT5A—cervical cancer	3.48e-05	0.00152	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TAAR6—cervical cancer	3.47e-05	0.00152	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—AKAP13—cervical cancer	3.4e-05	0.00149	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—MTHFR—cervical cancer	3.4e-05	0.00149	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	3.29e-05	0.00144	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—WNT5A—cervical cancer	3.21e-05	0.00141	CbGpPWpGaD
Clomipramine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	3.17e-05	0.00139	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—WNT5A—cervical cancer	3.17e-05	0.00139	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TAAR6—cervical cancer	3.16e-05	0.00138	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—WNT2—cervical cancer	3.12e-05	0.00137	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—NOTCH2—cervical cancer	2.94e-05	0.00129	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—WNT5A—cervical cancer	2.93e-05	0.00129	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CA9—cervical cancer	2.79e-05	0.00122	CbGpPWpGaD
Clomipramine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	2.75e-05	0.0012	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—AKAP13—cervical cancer	2.74e-05	0.0012	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—WNT2—cervical cancer	2.71e-05	0.00119	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	2.49e-05	0.00109	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—WNT2—cervical cancer	2.47e-05	0.00108	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—HES1—cervical cancer	2.41e-05	0.00106	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	2.4e-05	0.00105	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—AKAP13—cervical cancer	2.38e-05	0.00104	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—WNT5A—cervical cancer	2.37e-05	0.00104	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—NOTCH2—cervical cancer	2.26e-05	0.000988	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CA9—cervical cancer	2.2e-05	0.000964	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AKAP13—cervical cancer	2.17e-05	0.000949	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TERT—cervical cancer	2.11e-05	0.000926	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NOTCH2—cervical cancer	2.06e-05	0.000902	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—WNT5A—cervical cancer	2.06e-05	0.000901	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CA9—cervical cancer	1.97e-05	0.000865	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—FGFR3—cervical cancer	1.94e-05	0.00085	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CA9—cervical cancer	1.93e-05	0.000844	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.9e-05	0.000833	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—WNT5A—cervical cancer	1.87e-05	0.000819	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—HES1—cervical cancer	1.85e-05	0.00081	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—NOTCH1—cervical cancer	1.82e-05	0.000798	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CA9—cervical cancer	1.82e-05	0.000796	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—HES1—cervical cancer	1.69e-05	0.00074	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NOTCH2—cervical cancer	1.66e-05	0.000728	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—EGFR—cervical cancer	1.62e-05	0.000711	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TERT—cervical cancer	1.62e-05	0.00071	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.6e-05	0.0007	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CA9—cervical cancer	1.54e-05	0.000674	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—FGFR3—cervical cancer	1.49e-05	0.000652	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TERT—cervical cancer	1.48e-05	0.000648	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NOTCH2—cervical cancer	1.44e-05	0.000632	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—NOTCH1—cervical cancer	1.4e-05	0.000612	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—MTOR—cervical cancer	1.36e-05	0.000598	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—HES1—cervical cancer	1.36e-05	0.000597	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—FGFR3—cervical cancer	1.36e-05	0.000595	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NOTCH2—cervical cancer	1.31e-05	0.000575	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NOTCH1—cervical cancer	1.27e-05	0.000558	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CASP3—cervical cancer	1.26e-05	0.00055	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—EGFR—cervical cancer	1.24e-05	0.000545	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CTNNB1—cervical cancer	1.21e-05	0.00053	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TERT—cervical cancer	1.19e-05	0.000523	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CA9—cervical cancer	1.19e-05	0.00052	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—HES1—cervical cancer	1.18e-05	0.000518	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—EGFR—cervical cancer	1.14e-05	0.000498	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—MTHFR—cervical cancer	1.13e-05	0.000495	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—FGFR3—cervical cancer	1.1e-05	0.00048	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—HES1—cervical cancer	1.08e-05	0.000472	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—TP53—cervical cancer	1.06e-05	0.000464	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—STAT3—cervical cancer	1.05e-05	0.000462	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MTOR—cervical cancer	1.05e-05	0.000458	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TERT—cervical cancer	1.04e-05	0.000454	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NOTCH1—cervical cancer	1.03e-05	0.000451	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CASP3—cervical cancer	9.63e-06	0.000422	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—EGFR—cervical cancer	9.58e-06	0.00042	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MTOR—cervical cancer	9.55e-06	0.000418	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—FGFR3—cervical cancer	9.51e-06	0.000417	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TERT—cervical cancer	9.43e-06	0.000413	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CTNNB1—cervical cancer	9.28e-06	0.000406	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—EGFR—cervical cancer	9.16e-06	0.000401	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NOTCH1—cervical cancer	8.93e-06	0.000391	CbGpPWpGaD
Clomipramine—ALB—Metabolism—MTHFR—cervical cancer	8.93e-06	0.000391	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CASP3—cervical cancer	8.79e-06	0.000385	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—FGFR3—cervical cancer	8.65e-06	0.000379	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CTNNB1—cervical cancer	8.47e-06	0.000371	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TP53—cervical cancer	8.36e-06	0.000366	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NOTCH1—cervical cancer	8.13e-06	0.000356	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—STAT3—cervical cancer	8.09e-06	0.000354	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TP53—cervical cancer	8.05e-06	0.000353	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—MTHFR—cervical cancer	8.01e-06	0.000351	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—EGFR—cervical cancer	7.96e-06	0.000349	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—MTHFR—cervical cancer	7.82e-06	0.000343	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MTOR—cervical cancer	7.71e-06	0.000338	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—STAT3—cervical cancer	7.38e-06	0.000323	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—MTHFR—cervical cancer	7.37e-06	0.000323	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—EGFR—cervical cancer	7.35e-06	0.000322	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—EGFR—cervical cancer	7.24e-06	0.000317	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CASP3—cervical cancer	7.09e-06	0.000311	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CTNNB1—cervical cancer	6.83e-06	0.000299	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—EGFR—cervical cancer	6.71e-06	0.000294	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MTOR—cervical cancer	6.69e-06	0.000293	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—MTHFR—cervical cancer	6.24e-06	0.000274	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TP53—cervical cancer	6.17e-06	0.00027	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CASP3—cervical cancer	6.16e-06	0.00027	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MTOR—cervical cancer	6.09e-06	0.000267	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—STAT3—cervical cancer	5.96e-06	0.000261	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CTNNB1—cervical cancer	5.93e-06	0.00026	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TP53—cervical cancer	5.63e-06	0.000247	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CASP3—cervical cancer	5.6e-06	0.000245	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—EGFR—cervical cancer	5.41e-06	0.000237	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CTNNB1—cervical cancer	5.4e-06	0.000236	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—STAT3—cervical cancer	5.17e-06	0.000227	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—MTHFR—cervical cancer	4.82e-06	0.000211	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—STAT3—cervical cancer	4.71e-06	0.000206	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—EGFR—cervical cancer	4.7e-06	0.000206	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TP53—cervical cancer	4.55e-06	0.000199	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—EGFR—cervical cancer	4.28e-06	0.000187	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TP53—cervical cancer	3.95e-06	0.000173	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TP53—cervical cancer	3.59e-06	0.000157	CbGpPWpGaD
